According to the reports, one third of thyroid cancer metastases lost ability to concentrate iodine through dedifferentiation, and thus resistant to radioiodine therapy (28, 29), while Impact of TP53 alterations on PTC dedifferentiation has been well established and evaluated in mouse model with thyroid cancer (15). The gene discussed is TP53; the disease is thyroid gland carcinoma.